Lovastatin
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
Lovastatin: From Hyperlipidaemia to Homozygous Familial Hypercholesterolemia
One-Sentence Summary
Lovastatin is a statin (HMG-CoA reductase inhibitor) originally used to treat hyperlipidaemia and related lipid disorders, including atherosclerosis. The TxGNN model predicts it may be effective for homozygous familial hypercholesterolemia, but the supporting evidence is weak: 1 clinical trial (which tests a different drug) and 19 publications, mostly small case-level reports and reviews. Evidence is stronger for closely related lipid indications such as hyperlipoproteinemia and familial hypercholesterolemia, which are largely extensions of the original lipid-lowering use rather than new mechanisms.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hyperlipidaemia and related lipid disorders (hypertriglyceridemia, familial hyperlipidemia, atherosclerosis); the Singapore licence records contain no approved indication text |
| Predicted New Indication | Homozygous familial hypercholesterolemia |
| TxGNN Prediction Score | 99.89% |
| Evidence Level | L3 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 5 |
| Recommended Decision | Hold (for the top-ranked indication); Proceed with Guardrails for hyperlipoproteinemia and familial hypercholesterolemia |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on known pharmacology, lovastatin inhibits HMG-CoA reductase, the rate-limiting enzyme of cholesterol synthesis. This lowers intracellular cholesterol and upregulates LDL receptors in the liver, which increases LDL clearance from the blood.
This is why the prediction is only partly convincing. In homozygous familial hypercholesterolemia, the benefit of a statin depends on how much LDL receptor activity the patient still has. A study of three children with receptor-negative disease found no fall in LDL-cholesterol on lovastatin (PMID 3397806). In contrast, small reports describe benefit in patients with some residual receptor function, usually in combination with other agents (PMID 1785747, PMID 3534334). The prediction is therefore biologically plausible, but it is a close extension of the original lipid-lowering use, not a new-mechanism repurposing. Response is expected to vary by patient genotype.
Clinical Trial Evidence
Only one registered trial is linked to the top-ranked indication, and it does not test lovastatin.
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT03510715 | Phase 3 | Completed | 18 | Open-label alirocumab (a PCSK9 inhibitor) in children and adolescents aged 8–17 with homozygous FH; assesses LDL-C at Week 12. Gives disease context only, not evidence for lovastatin. |
For related predicted indications, direct lovastatin trials do exist:
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00116870 | Phase 2/3 | Completed | 270 | Double-blind, placebo-controlled angiographic study of lovastatin on coronary atherosclerosis progression in patients with coronary heart disease (hyperlipoproteinemia and FH indications) |
| NCT00345657 | Phase 4 | Completed | 100 | Extended-release niacin/lovastatin versus usual care for dyslipidaemia in primary care; lovastatin effect confounded by the combination |
| NCT00721305 | Phase 2 | Completed | 112 | Randomized trial of lovastatin's antiretroviral effect in HAART-naive HIV-1-infected individuals |
Literature Evidence
Most literature for homozygous FH is small, older, and case-level.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 3397806 | 1988 | Clinical study | J Pediatr | Three children with receptor-negative homozygous FH: lovastatin did not lower LDL-C or change LDL turnover |
| 1785747 | 1991 | Clinical study | An Esp Pediatr | Two homozygous FH patients treated with lovastatin plus probucol and cholestyramine; LDL receptor analysis and response studied |
| 3534334 | 1986 | Case report | JAMA | Child with homozygous FH after liver transplantation reached normal cholesterol with lovastatin |
| 2252289 | 1990 | Case report | An Esp Pediatr | Response to combined cholestyramine and lovastatin in a receptor-defective homozygous FH patient |
| 2209665 | 1990 | Case report | Eur J Pediatr | 7-year-old girl treated with LDL plasmapheresis, with and without lovastatin |
| 2912429 | 1989 | Review | Arteriosclerosis | Plasma exchange and LDL apheresis in homozygous FH; lovastatin plus apheresis under assessment |
| 2042836 | 1991 | Review | Ann N Y Acad Sci | Drug and surgical treatment of dyslipidaemia in children; lovastatin among the agents used |
| 12063772 | 2001 | Review | Nutr Metab Cardiovasc Dis | Rationale and timing of statin use in children with FH |
| 3278832 | 1988 | Review | Clin Pharm | Pharmacology, efficacy and adverse effects of lovastatin |
| 2912428 | 1989 | Clinical study | Arteriosclerosis | Drug treatment of FH in children, including three homozygous patients |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN09664P | AA PHARMA LOVASTATIN TABLET 20 mg | Tablet | Not stated in the licence record |
| SIN09663P | AA PHARMA LOVASTATIN TABLET 40 mg | Tablet | Not stated in the licence record |
| SIN12329P | LOVASTIN TABLET 20 mg | Tablet | Not stated in the licence record |
| SIN10073P | LOCHOL TABLET 20 mg | Tablet | Not stated in the licence record |
| SIN10001P | MEDOSTATIN TABLET 20 mg | Tablet | Not stated in the licence record |
All five licences are valid single-ingredient oral tablets; none are cancelled.
Safety Considerations
- Contraindication-related conditions (from a knowledge graph, not label text): liver disease, gallbladder disease, thrombocytopenia, hyperglycaemia, diabetes mellitus and diabetic ketoacidosis, peptic ulcer disease, myopathy and other muscle disease, rhabdomyolysis, gout, hypotensive disorder, blood coagulation disease, acute coronary syndrome, myocardial infarction, coronary artery disease, hemoglobinopathy and hypophosphatemia. These should be confirmed against the official package insert, because graph edges are not label wording.
- Drug Interactions: 100 interactions were identified. Major: clarithromycin. Moderate: aprepitant, omeprazole, esomeprazole, lansoprazole, pantoprazole, metronidazole, tinidazole, cimetidine, clotrimazole, miconazole, naltrexone, eluxadoline, pectin, rosuvastatin, simvastatin and troglitazone. Other lipid-lowering agents (fibrates, niacin) raise myopathy risk.
- HIV protease inhibitors: lovastatin is a CYP3A4 substrate, and combination with HIV protease inhibitors markedly increases exposure and myopathy risk (PMID 23703578).
- Special populations: use in children and adolescents requires growth and maturation monitoring, and females of reproductive age need contraception counselling.
Package insert warnings and contraindications were not available for this report; please refer to the package insert for authoritative safety information.
Conclusion and Next Steps
Decision: Hold (for homozygous familial hypercholesterolemia, the top-ranked prediction)
Rationale:
- The prediction score is very high (99.89%), but the supporting evidence is limited to small, mostly decades-old case-level reports, and the one registered trial tests a different drug. Evidence from a small paediatric study shows no LDL-C response in receptor-negative disease, so benefit is likely restricted to patients with residual LDL receptor function.
- By contrast, hyperlipoproteinemia and familial hypercholesterolemia / autosomal dominant hypercholesterolemia have stronger support (a Phase 2/3 placebo-controlled lovastatin trial and adolescent FH studies) and could be considered Proceed with Guardrails. These are extensions of the existing lipid-lowering use.
- Other predictions (CYP7A1 deficiency, CETP deficiency, hepatic lipase deficiency, the neurodevelopmental disorder, and SIV infection) have no meaningful evidence and should be held. The HIV indication has a Phase 2 trial but needs its clinical endpoints confirmed and carries a significant protease-inhibitor interaction concern.
To proceed, the following is needed:
- Genotype-stratified (receptor-negative vs receptor-defective) efficacy data for lovastatin in homozygous FH
- Singapore package insert warnings and contraindications, and approved indication text for the five licences
- Detailed mechanism of action data
- A monitoring plan covering myopathy, liver enzymes, CYP3A4 and fibrate interactions, and paediatric growth
- Confirmation of the HIV trial endpoints (PMID 23085245) before considering that indication further
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.